


Abstract

N-Aminoimidazolone (Nai) residues adopt β - and γ -turn conformers in model peptides. Notably, 5-substituted Nai peptides show promise for mimicry of both turn backbone and side chain function and geometry. Regioselective synthesis of 5-substituted Nai residues has now been achieved by a route featuring proline-catalyzed condensations of azopeptides and aldehydes.


Introduction: Nai peptide conception

Mimicry of peptide turn geometry has warranted focus due to implications in molecular recognition. Replacement of an amino amide residue by a semicarbazide in so called **azapeptides (1)** has favored turn geometry and improved duration of action by way of stereo-electronic effects due to hydrazine nitrogen lone pair-lone pair repulsion and urea planarity [1]. α -Amino- γ -lactam (**Agl, 2**) residues, so-called Freidinger-veber lactams, have been employed to restrict covalently backbone ψ - and ω -dihedral angles to favor turn geometry [2]. Combining properties of aza and Agl constraints, N-aminoimidazolone (**Nai, 3**) residues were conceived to promote peptide turn conformations with potential to introduce and restrain side chain function at the heterocycle 4- and 5-positions [3].



4-Substituted Nai synthesis


Model 4-substituted Nai dipeptides exhibit turn geometry in X-ray and NMR spectroscopic analyses. They have been synthesized by routes featuring Sonogashira couplings on azaPra residues, base-promoted 5-endo-dig cyclization and olefin isomerization, but ester epimerization occurred during alkaline-mediated cyclization [4,5].



Peptide	ϕ^{i+1}	ψ^{i+1}	ϕ^{i+2}	ψ^{i+2}
Ideal type II' β -turn	60	-120	-80	0
<i>p</i> -MeOBz-4-Me-Nai-D-Phe-NHiPr	58.9	-153.3	-69.1	-4.6


4,5-Disubstituted Nai synthesis

Computational analysis of 4-methyl,5-aryl Nai residues indicated replication of natural side chain orientation and β -turn conformation [6].



Peptide	ϕ^{i+1}	ψ^{i+1}	ϕ^{i+2}	ψ^{i+2}	χ^1	χ^2
Ideal type II' β -turn	60	-120	-80	0	-	-
<i>p</i> -MeOBz-4-Me-Nai-D-Phe-NHiPr	58.9	-153.3	-69.1	-4.6	-	-
<i>p</i> -MeOBz-4-Me,5- <i>p</i> -HOPh-Nai-D-Phe-NHiPr	48.6	-143.7	-62.4	33.6	-41.1	76.0


5-Substituted (4-Me)Nai analog synthesis used Pd-catalyzed arylation and Vilsmeier-Haack formylation chemistry [6, 7]




Goals:

- Synthesis of 5-substituted Nai residues
- Diversification of 5-substituted Nai side chains
- Incorporation into biologically active peptide

Azapeptide synthesis and pericyclic chemistry [8]



Synthesis of 5-substituted Nai derivatives [9]




9	R ⁴	R ⁵	R ²	(%)
a	Bn	<i>i</i> -Pr	Bn	85
b	Fm	<i>i</i> -Pr	Bn	89
c	Bn	Me	Bn	91
d	Fm	Me	<i>i</i> -Pr	83
e	Fm	Me	Bn	73
f	Bn	Et	Bn	65
g	Fm	Et	Bn	80
h	Bn	<i>n</i> -Pr	Bn	83
i	Fm	Ph	Me	68
j	Fm	Ph	Bn	65
k ^[a]	Fm	Ph	Bn	43
l	Bn	<i>p</i> -(HO)Ph	Bn	74
m ^[a]	Fm	<i>p</i> -(TBSO)Ph	Bn	44
n	Bn	(CH ₂) ₂ CO ₂ <i>t</i> -Bu	Bn	60
o	Bn	(CH ₂) ₂ NHBoc	Bn	65


^[a]D-Isomer

Synthesis and biomedical application of Nai peptides: [5-Aryl-Nai⁴]GHRP-6

GHRP-6 (HwAWfK) is a synthetic peptide that binds to the GHS-R1a and CD-36 receptors. Replacement of Trp⁴ with aza-Tyr⁴ provided a CD-36 selective azapeptide with antiangiogenic and anti-inflammatory activities in animal models [10]. [5-Aryl-Nai⁴]GHRP-6 analogs **19** and **20** have been synthesized to explore the influence of conformational constraint on activity.



[(5-aryl)Nai]-GHRP-6 analogs **19** and **20** behaved similarly to [azaTyr⁴]-GHRP-6 (**15**) exhibiting (A) ability to reduce TLR-2 agonist-induced NO production and (B) CD36 binding affinity (μ M IC₅₀) in a competition assay with photoactivatable ¹²⁵I-Tyr-Bpa-Ala-hexarelin: hexarelin (4.0), **15** (3.1), **19** (8.1), **20** (10.0), Δ . A common turn conformer may account for their similar activity.



Conclusions

- 5-Substituted Nai synthesis provides mimics of β -turn backbone and side chain geometry and function.
- Various 5-position substituents were introduced by using different aldehyde partners in proline-catalyzed condensations with azopeptides.
- Incorporation of 5-aryl Nai residues into GHRP-6 analogs indicates a bioactive β -turn geometry with aza-residue in *i*+1 position with *gauche* side chain orientation.

References

- Chingle, R.; Proulx, C.; Lubell, W.D. *Acc. Chem. Res.* **2017**, *50*, 1541–1556.
- Freidinger, R. M.; Veber, D. F.; Perlow, D. S.; Brooks, J. R.; Saperstein, R. *Science*, **1980**, *210*, 656–658.
- St-Cyr, D. J.; García-Ramos, Y.; Doan, N. D.; Lubell, W. D. *Peptidomimetics – I*, Springer, **2017**, 125–175
- Proulx, C.; Lubell, W. D. *Org. Lett.*, **2012**, *14*, 4552.
- Proulx, C.; Lubell, W. D. *Peptide Science*, **2014**, *102*, 7-15.
- Poupert, J.; Doan-Ngoc, D.; Bérubé, D.; Hamdane, Y.; Medena, C.; Lubell, W. D. *Heterocycles*, **2019**, *99*, 279-293.
- Poupert, J.; Hamdane, Y.; Lubell, W. D. *Can. J. Chem.* **2020**, *98*, 278-284.
- Chingle, R.; Lubell, W.D. *Org. Lett.*, **2015**, *17*, 5400–5403.
- Hamdane, Y.; Chauhan, S. P.; Vutla, S.; Mulumba, M.; Ong, H.; Lubell, W. D. *Org. Lett.* **2021**, *23* (9), 3491–3495.
- Mellal, K.; Omri, S.; Mulumba, M.; Tahiri, H.; Fortin, C.; Dorion, M.-F.; Pham, H.; Ramos, Y.G.; Zhang, J.; Pundir, S.; Joyal, J.-S.; Bouchard, J.-F.; Sennlaub, F.; Febbraio, M.; Hardy, P.; Gravel, S.-P.; Marleau, S.; Lubell, W.D.; Chemtob, S.; Ong, H. *Sci. Rep.* **2019**, *9*, 12903.

Acknowledgements

We thank Drs. A. Furtos and P. Aguiar of the regional centers of mass spectrometry and NMR spectroscopy at the Université de Montréal for help with analyses. Financial support is acknowledged from NSERC, CIHR, FRQNT and Mperia Therapeutics, Inc. We also thank the CCVC.